GO:0005459 UDP-galactose transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005459 describes the molecular function that moves UDP-galactose across a membrane, a rate-limiting step for galactosylation reactions inside the Golgi and ER.
• The founding genes are the SLC35 family members SLC35A2 (human UDP-galactose transporter) and its yeast orthologs Gms1p in Schizosaccharomyces pombe and the murine Had-1 locus.
• Substrate recognition depends on transmembrane domains and hydrophilic loop residues, as shown by chimeric and deletion-mutant analyses of UDP-galactose and CMP-sialic acid transporters.
• Loss of UDP-galactose transport causes defective protein and lipid galactosylation, which is linked to congenital disorders of glycosylation and altered Shiga toxin binding.
• Plant and rice nucleotide sugar transporters can also carry UDP-galactose, showing that this activity is evolutionarily conserved beyond mammals.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools for dissecting SLC35A2-dependent UDP-galactose transport in disease and glycobiology.
Description
UDP-galactose transmembrane transporter activity (GO:0005459) is the molecular function that enables the transfer of UDP-galactose from one side of a membrane to the other, where UDP-galactose is a nucleotide sugar composed of galactose in glycosidic linkage with uridine diphosphate. This activity is essential because galactose must be delivered as an activated donor into the lumen of the Golgi apparatus and endoplasmic reticulum for galactosyltransferase-mediated glycosylation of proteins and lipids. Without a dedicated transporter, UDP-galactose cannot cross the lipid bilayer, and galactosylation reactions stall. The function was first characterized genetically in the fission yeast Schizosaccharomyces pombe, where Gms1p was shown to be the UDP-galactose transporter required for normal cell wall galactomannan synthesis. In mammals, the orthologous activity is carried out by SLC35A2, and its defect underlies the murine Had-1 phenotype and human glycosylation disorders. Researchers study GO:0005459 because it sits at the interface of nucleotide sugar metabolism, Golgi homeostasis, and human disease. The activity is also experimentally tractable: bacterial Shiga toxins bind to galactose-terminated glycans and can be used as a sensitive readout of UDP-galactose transport in cells. Chimeric transporter constructs between the human UDP-galactose transporter and the CMP-sialic acid transporter have further defined which domains and residues dictate substrate specificity. This article integrates the QuickGO definition with verified primary literature to summarize the mechanism, key genes, disease links, and CRISPR-based research strategies for GO:0005459.
UDP-galactose transmembrane transporter activity At A Glance
| GO ID | GO:0005459 |
|---|---|
| GO term | UDP-galactose transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transfers UDP-galactose across a membrane to supply the substrate for galactosylation reactions |
| Substrate | UDP-galactose (galactose linked to uridine diphosphate) |
| Representative genes | SLC35A2 (human), Gms1p (Schizosaccharomyces pombe), Had-1 (mouse) |
| Cellular context | Golgi apparatus and endoplasmic reticulum membranes |
| Related activity | CMP-sialic acid transporter activity, which shares structural features and can be studied with chimeric constructs |
What Is GO:0005459?
GO:0005459 is a molecular function term in the Gene Ontology. It describes the ability of a protein to move UDP-galactose across a biological membrane, from one side to the other. UDP-galactose is a nucleotide sugar in which galactose is linked through a glycosidic bond to uridine diphosphate. The term does not describe a signaling event or a biosynthetic reaction; it specifically captures the transport step that delivers the activated galactose donor to the compartment where galactosyltransferases use it. In practice, this activity is measured as UDP-galactose uptake into membrane vesicles or as restoration of galactosylation in transporter-deficient cells.
Why Is UDP-galactose transmembrane transporter activity Important in Cell Biology?
UDP-galactose transmembrane transporter activity is important because it controls the supply of activated galactose for all galactose-containing glycoconjugates, including glycoproteins, glycolipids, and glycosaminoglycans. When this activity is lost, cells cannot galactosylate their secretory cargo properly, leading to defective protein folding, altered cell-surface receptor function, and disease. The activity is also a determinant of host-pathogen interactions, since galactose-terminated glycans are receptors for bacterial Shiga toxins. Because the transporter is genetically tractable in yeast, mouse, and human cells, it serves as a model for understanding nucleotide sugar transporter structure-function relationships and for developing glycosylation-targeted therapeutics.
• Provides the essential donor substrate for galactosyltransferases in the Golgi and ER.
• Defects cause abnormal protein and lipid glycosylation, a hallmark of congenital disorders of glycosylation.
• Determines cell-surface glycan display and thus modulates receptor signaling and cell adhesion.
• Controls sensitivity to Shiga toxins and related bacterial lectins that bind galactose-terminated glycans.
• Is conserved from yeast to plants, making it a general model for nucleotide sugar transport.
• Its substrate specificity can be dissected using chimeras with the CMP-sialic acid transporter.
• Transmembrane domains and hydrophilic loops are critical for its function, as shown by deletion and point-mutant analyses.
• Altered UDP-galactose transport is relevant to cancer glycobiology and immune recognition, although direct clinical evidence is still emerging.
• It is a target for CRISPR-based functional genomics because loss-of-function phenotypes are measurable by lectin or toxin binding.
• Studying it informs the design of glycoengineered cells for biopharmaceutical production.
What Happens During UDP-galactose transmembrane transporter activity?
Substrate recognition at the membrane
In simple terms: The transporter first recognizes UDP-galactose as its cargo.
The transporter must distinguish UDP-galactose from other nucleotide sugars such as CMP-sialic acid and UDP-glucose. Studies on the human UDP-galactose transporter and the related CMP-sialic acid transporter show that substrate specificity is determined by specific amino acid residues in transmembrane domains and hydrophilic loops. In the fission yeast Schizosaccharomyces pombe, Gms1p was functionally characterized as a UDP-galactose transporter required for galactomannan synthesis, confirming that recognition is an intrinsic property of the transporter protein. Rice nucleotide sugar transporters can also transport UDP-galactose and UDP-glucose, indicating that the recognition pocket tolerates some variation across species.
Translocation across the lipid bilayer
In simple terms: After binding, the transporter flips UDP-galactose to the other side of the membrane.
Translocation is the core catalytic step of GO:0005459. The transporter forms a channel-like pathway through the membrane that allows the hydrophilic nucleotide sugar to cross the hydrophobic bilayer. Deletion and point-mutation analyses of the murine Had-1 UDP-galactose transporter demonstrated that transmembrane domains are indispensable for this step, and that loss of specific domains abolishes transport activity. Chimeric molecules between the human UDP-galactose transporter and the CMP-sialic acid transporter retain transport function only when the correct transmembrane architecture is preserved, showing that the physical path of translocation is structurally encoded.
Delivery to the Golgi lumen
In simple terms: The transporter delivers UDP-galactose into the Golgi, where it is used to build glycans.
Once UDP-galactose reaches the lumenal side of the Golgi membrane, it becomes the substrate for galactosyltransferases that add galactose to growing glycan chains. This delivery function is what makes GO:0005459 rate-limiting for galactosylation. In SLC35A2-deficient cells, defective UDP-galactose transport leads to reduced galactosylation, which can be measured by altered binding of Shiga toxins that recognize galactose-terminated glycans. The same principle applies in yeast, where loss of Gms1p impairs galactomannan biosynthesis.
Coupling to nucleotide sugar metabolism
In simple terms: The transporter works together with the enzymes that make and use UDP-galactose.
UDP-galactose is synthesized in the cytosol and consumed in the Golgi lumen, so the transporter must be functionally coupled to both production and consumption pathways. This coupling is evident from the fact that transporter deficiency produces phenotypes similar to those of galactosylation enzyme defects. The activity is therefore not an isolated event but part of a metabolic relay that maintains nucleotide sugar homeostasis across membrane compartments.
Key Genes Involved in GO:0005459 UDP-galactose transmembrane transporter activity
The following genes and proteins are directly implicated in UDP-galactose transmembrane transporter activity or have been used experimentally to study it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC35A2 | Human UDP-galactose transporter; mediates Golgi import of UDP-galactose | Mutations cause glycosylation defects; used in Shiga toxin binding assays |
| Gms1p | Fission yeast UDP-galactose transporter required for galactomannan synthesis | Founding genetic model for GO:0005459 |
| Had-1 | Murine locus encoding UDP-galactose transporter activity | Deficient mutant cells used to map essential transmembrane domains |
| SLC35A1 | CMP-sialic acid transporter; structurally related to UDP-galactose transporter | Used in chimeric constructs to define substrate specificity |
| UGT1 | Rice nucleotide sugar transporter capable of transporting UDP-galactose | Demonstrates conservation of UDP-galactose transport in plants |
| UGT2 | Rice nucleotide sugar transporter with UDP-galactose transport activity | Comparative substrate specificity studies |
| GAL7 | Yeast enzyme that produces UDP-galactose | Upstream metabolic context for transporter substrate supply |
| GAL10 | Yeast enzyme interconverting UDP-galactose and UDP-glucose | Metabolic context for nucleotide sugar pools |
| B4GALT1 | Galactosyltransferase that consumes UDP-galactose in the Golgi | Downstream enzyme whose activity depends on transporter function |
| ST3GAL1 | Sialyltransferase that competes for nucleotide sugar transport | Used in comparative studies with CMP-sialic acid transporter |
| SLC35A3 | Related nucleotide sugar transporter | Provides evolutionary context for SLC35 family substrate specificity |
| SLC35B1 | Related nucleotide sugar transporter | Comparative analysis of transporter families |
| SLC35C1 | GDP-fucose transporter | Used as an outgroup in transporter specificity studies |
| SLC35D1 | UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter | Related family member for phylogenetic comparison |
| Shiga toxin B subunit | Bacterial lectin that binds galactose-terminated glycans | Functional readout for UDP-galactose transport activity |
How Is UDP-galactose transmembrane transporter activity Regulated?
UDP-galactose transmembrane transporter activity is regulated at multiple levels. Transcriptional control of SLC35A2 and related transporters determines the available transport capacity, while post-translational modifications and interactions with other Golgi proteins may modulate activity. Substrate availability is a key regulator: the concentration of cytosolic UDP-galactose, which depends on galactose metabolism and UDP-glucose epimerization, directly influences transport rates. In addition, the lipid environment and membrane composition of the Golgi can affect transporter conformation and function, as suggested by the importance of transmembrane domains. Competition with other nucleotide sugar transporters for shared structural features may also influence specificity, as shown by chimeric transporter studies. However, specific signaling pathways such as mTOR or the integrated stress response have not been directly linked to this transporter in the verified literature, so they are not claimed here.
UDP-galactose transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC35A2 | Congenital disorder of glycosylation with neurological symptoms | Patient-derived fibroblasts or CRISPR knock-in of patient mutations |
| Had-1 | Murine glycosylation defect | Had-1 mutant cell lines and deletion mutants |
| Gms1p | Yeast cell wall galactomannan defect | Schizosaccharomyces pombe gms1 deletion strains |
| SLC35A1 | CMP-sialic acid transport deficiency | Chimeric transporter constructs in mammalian cells |
| B4GALT1 | Galactosylation-dependent pathologies | CRISPR knockout of B4GALT1 as downstream comparison |
Congenital disorders of glycosylation
Defects in UDP-galactose transmembrane transporter activity cause abnormal glycosylation of proteins and lipids. SLC35A2 mutations are associated with a congenital disorder of glycosylation characterized by developmental delay, seizures, and hypotonia. Functional studies using Shiga toxin binding as an assay have confirmed that SLC35A2 mutations reduce UDP-galactose transport and downstream galactosylation. The murine Had-1 mutant, which lacks UDP-galactose transporter activity, shows similar glycosylation defects and has been used to map the molecular requirements for transport.
Host-pathogen interactions
Galactose-terminated glycans on the cell surface serve as receptors for bacterial Shiga toxins. Because UDP-galactose transport determines the presence of these glycans, changes in transporter activity directly affect toxin binding and cellular susceptibility. This principle has been exploited experimentally: SLC35A2 activity can be measured by the binding of bacterial Shiga toxins to cells, providing a sensitive and specific assay for the transporter.
Cancer glycobiology
Altered glycosylation is a hallmark of cancer, and changes in nucleotide sugar transporter expression can contribute to tumor-associated glycan patterns. Although direct evidence linking GO:0005459 to specific cancers is limited in the verified literature, the dependence of galactosylation on UDP-galactose transport suggests that transporter dysregulation could influence cell adhesion, signaling, and immune recognition. Further research using CRISPR models is needed to establish causal roles.
From UDP-galactose transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC35A2 abolish UDP-galactose transport? | CRISPR knockout of SLC35A2 in human cell lines, measured by Shiga toxin binding |
| Which transmembrane domains are essential for transport? | Deletion mutants of Had-1 transporter expressed in deficient cells |
| Which residues determine substrate specificity? | Point mutations in chimeric UDP-galactose/CMP-sialic acid transporters |
| Can a tagged transporter be localized in the Golgi? | Knock-in of fluorescent or epitope tags at the endogenous SLC35A2 locus |
| Does overexpression increase galactosylation? | Overexpression of SLC35A2 in mammalian cells followed by lectin or toxin binding |
| Is the activity conserved in plants? | Expression of rice nucleotide sugar transporters in yeast or plant cells |
How to Study the UDP-galactose transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive UDP-galactose uptake | Direct transport activity | Characterization of wild-type and mutant transporters |
| Shiga toxin binding assay | Galactose-terminated glycan levels | Functional readout for SLC35A2 activity |
| Chimeric transporter analysis | Substrate specificity determinants | Mapping domains required for UDP-galactose transport |
| Site-directed mutagenesis | Role of specific amino acid residues | Identifying essential residues in transmembrane domains |
| Lectin staining | Cell-surface galactosylation | Assessing glycosylation status in knockout cells |
| CRISPR knockout screens | Genes affecting transport activity | Discovery of novel regulators |
| Fluorescent tagging and imaging | Subcellular localization of transporter | Confirming Golgi localization of SLC35A2 |
| Heterologous expression in yeast | Functional conservation of plant transporters | Testing rice nucleotide sugar transporters |
Transport assays with radioactive or fluorescent UDP-galactose
Direct measurement of UDP-galactose transmembrane transporter activity can be performed using membrane vesicles or permeabilized cells incubated with radiolabeled or fluorescently labeled UDP-galactose. Uptake is quantified by scintillation counting or fluorescence detection. This approach has been used to characterize Gms1p in fission yeast and the human SLC35A2 transporter.
Shiga toxin binding as a functional readout
Because Shiga toxins bind galactose-terminated glycans, their binding to cells provides a sensitive proxy for UDP-galactose transport activity. This assay was developed for SLC35A2 and can distinguish wild-type from mutant transporter function without the need for radioactive substrates.
Chimeric transporter and mutagenesis studies
Domain-swapping between the UDP-galactose transporter and the CMP-sialic acid transporter, combined with site-directed mutagenesis, has been used to identify the structural determinants of substrate specificity. These methods reveal which transmembrane domains and loop residues are required for UDP-galactose recognition and translocation.
CRISPR-based genetic screens
Pooled CRISPR knockout screens targeting SLC35 family genes and glycosylation pathways can identify genes that modify UDP-galactose transport activity. Cells are selected based on lectin or toxin binding, and enriched sgRNAs are identified by next-generation sequencing. This approach is powerful for discovering novel regulators of GO:0005459.
How CRISPR Can Be Used to Study GO:0005459 UDP-galactose transmembrane transporter activity
Knockout
CRISPR knockout of SLC35A2 or its orthologs is the most direct way to eliminate UDP-galactose transmembrane transporter activity. Knockout cells show reduced galactosylation, which can be measured by Shiga toxin binding or lectin staining. In yeast, deletion of gms1 produces a cell wall galactomannan defect. Knockout models are essential for establishing causality between the transporter and downstream phenotypes.
Point Mutation
CRISPR-mediated point mutations can recreate patient-derived missense mutations in SLC35A2 or introduce mutations in residues identified as critical for substrate recognition. Such models allow precise testing of how specific amino acid changes affect UDP-galactose transport without confounding effects from complete loss of protein.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or reporter cassettes at the endogenous SLC35A2 locus enables real-time tracking of transporter localization and expression. This approach preserves endogenous regulatory elements and provides a physiological context for studying GO:0005459.
Overexpression
Overexpression of SLC35A2 or related transporters can enhance UDP-galactose transport and increase galactosylation of secreted proteins. This strategy is useful for glycoengineering applications and for testing whether increased transport capacity can rescue glycosylation defects caused by other mutations.
How EDITGENE Supports UDP-galactose transmembrane transporter activity Research
Researchers studying UDP-galactose transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, glycosylation, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for UDP-galactose transmembrane transporter activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLC35A2 Knockout HEK293 Cell Line | EDJ-KQ3494 | Human | 7355 | Details Get a Quote |
| SLC35A2 Knockout A-549 Cell Line | EDJ-KQ25287 | Human | 7355 | Details Get a Quote |
| SLC35A2 Knockout HCT 116 Cell Line | EDJ-KQ25288 | Human | 7355 | Details Get a Quote |
| SLC35A2 Knockout HeLa Cell Line | EDJ-KQ25289 | Human | 7355 | Details Get a Quote |
| SLC35A3 Knockout HEK293 Cell Line | EDJ-KQ51106 | Human | 23443 | Details Get a Quote |
| SLC35A3 Knockout HeLa Cell Line | EDJ-KQ55742 | Human | 23443 | Details Get a Quote |
| SLC35A3 Knockout A-549 Cell Line | EDJ-KQ64240 | Human | 23443 | Details Get a Quote |
| SLC35A3 Knockout HCT 116 Cell Line | EDJ-KQ72685 | Human | 23443 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About UDP-galactose transmembrane transporter activity
What is UDP-galactose transmembrane transporter activity?
It is a molecular function (GO:0005459) that moves UDP-galactose across a membrane, supplying the activated galactose donor for glycosylation reactions in the Golgi and ER.
What genes are involved in UDP-galactose transmembrane transporter activity?
The main genes are SLC35A2 in humans, Gms1p in fission yeast, and the Had-1 locus in mice. Related transporters include SLC35A1 and plant nucleotide sugar transporters.
Which diseases are linked to UDP-galactose transporter defects?
Mutations in SLC35A2 cause a congenital disorder of glycosylation with neurological symptoms. Defective transport also alters Shiga toxin susceptibility.
How is UDP-galactose transport measured in the lab?
Common methods include radioactive UDP-galactose uptake assays, Shiga toxin binding, and lectin staining of cell-surface glycans.
What is the role of SLC35A2 in glycosylation?
SLC35A2 transports UDP-galactose into the Golgi lumen, where galactosyltransferases use it to add galactose to proteins and lipids. Loss of SLC35A2 reduces galactosylation.
Can CRISPR be used to study UDP-galactose transporters?
Yes. CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect transporter function and substrate specificity.
Is UDP-galactose transport conserved in plants?
Yes. Rice nucleotide sugar transporters can transport UDP-galactose and UDP-glucose, showing conservation of this activity beyond mammals.
What are the key structural features of UDP-galactose transporters?
Transmembrane domains and hydrophilic loop residues are essential for substrate recognition and translocation, as shown by deletion and chimeric studies.
How does UDP-galactose transport affect Shiga toxin sensitivity?
Galactose-terminated glycans produced via UDP-galactose transport serve as Shiga toxin receptors. Cells with defective transport show reduced toxin binding.
What model systems are best for studying GO:0005459?
Fission yeast, murine Had-1 cells, human cell lines with SLC35A2 mutations, and heterologous expression systems are all valuable models.
Conclusion
UDP-galactose transmembrane transporter activity (GO:0005459) is a fundamental molecular function that bridges nucleotide sugar metabolism and protein glycosylation. Its founding characterization in yeast and mammals has revealed conserved structural requirements for substrate recognition and translocation, and its dysfunction is linked to congenital glycosylation disorders and altered host-pathogen interactions. CRISPR-based models, combined with functional assays such as Shiga toxin binding and lectin staining, provide powerful tools to dissect this activity in health and disease. Continued research into GO:0005459 will inform glycoengineering strategies and therapeutic approaches for glycosylation-related disorders.
References
- 1. Tanaka N et al.. 2001. Functional characterization of Gms1p/UDP-galactose transporter in Schizosaccharomyces pombe.. Yeast 18(8):745-57 PMID: 11378902
- 2. Li D et al.. 2019. Functional analyses of the UDP-galactose transporter SLC35A2 using the binding of bacterial Shiga toxins as a novel activity assay.. Glycobiology 29(6):490-503 PMID: 30834435
- 3. Aoki K et al.. 1999. Expression and activity of chimeric molecules between human UDP-galactose transporter and CMP-sialic acid transporter.. J Biochem 126(5):940-50 PMID: 10544289
- 4. Ishida N et al.. 1999. Indispensability of transmembrane domains of Golgi UDP-galactose transporter as revealed by analysis of genetic defects in UDP-galactose transporter-deficient murine had-1 mutant cell lines and construction of deletion mutants.. J Biochem 126(6):1107-17 PMID: 10578063
- 5. Takeshima-Futagami T et al.. 2012. Amino acid residues important for CMP-sialic acid recognition by the CMP-sialic acid transporter: analysis of the substrate specificity of UDP-galactose/CMP-sialic acid transporter chimeras.. Glycobiology 22(12):1731-40 PMID: 22833315
- 6. Chan KF et al.. 2010. Identification of essential amino acid residues in the hydrophilic loop regions of the CMP-sialic acid transporter and UDP-galactose transporter.. Glycobiology 20(6):689-701 PMID: 20181793
- 8. Seino J et al.. 2010. Characterization of rice nucleotide sugar transporters capable of transporting UDP-galactose and UDP-glucose.. J Biochem 148(1):35-46 PMID: 20305274
